Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Prostate. 2019 Oct 29;80(1):88–98. doi: 10.1002/pros.23921

FIGURE 8.

FIGURE 8

Inhibition of subcutaneous tumor growth by docetaxel and FABP5 inhibitors. PC3 cells (1 × 106) were implanted subcutaneously into male BALB/c nude mice. From day 15 onwards, mice were treated with vehicle, SBFI-102 (20 mg/kg, daily) in combination with docetaxel (5 mg/kg, weekly), SBFI-103 (20 mg/kg, daily) in combination with docetaxel (5 mg/kg, weekly), or docetaxel (5 mg/kg or 10 mg/kg, weekly). A, Tumor growth over the time course of treatments. B-D, Tumor volumes at days 25, 30, and 35, respectively. **P < .01 versus vehicle treatment; ***P < .001 versus vehicle treatment; #P < .05 versus 10 mg/kg docetaxel treatment; NS versus 10 mg/kg docetaxel treatment; (n = 5). FABP5, fatty acid-binding protein; SBFI, Stony Brook fatty acid-binding protein inhibitor; NS, no significance [Color figure can be viewed at wileyonlinelibrary.com]